Research Summary

Dr. Cooperberg has a long experience in prostate cancer clinical and outcomes research, with specific areas of interest including early detection, risk assessment, biomarker validation, health services research, oncologic and health-related quality of life outcomes, comparative effectiveness, and disparities research. He has an extensive research history with CaPSURE and other registry and our institutional databases and tissue bank. He has a strong research interest in prostate cancer risk assessment, and led development and validation of the UCSF Cancer of the Prostate Risk Assessment (CAPRA) pre- and post-operative scores, as well as validation multiple tissue-based genomic markers now in wide clinical use.

From 2013 to 2020 he served as Associate Editor for European Urology, the leading peer-reviewed journal in urology, and as of 2023 am Associate Editor for the Journal of the National Cancer Institute. He also served as the physician lead on the American Urological Association’s new AUA Quality (AQUA) national disease registry with goals of documentation practice patterns, quality of care, and outcomes for patients across the nation with urologic diseases. In 2015, Cooperberg won the AUA Gold Cystoscope Award, awarded annually to one urologist based on contributions to the field within the first ten years of practice.

He has a longstanding interest in the development and validation of prostate cancer imaging tests and other biomarkers for prognostic risk, and led the pivotal validation studies for two of the three commercial tissue tests currently on the market for newly diagnosed prostate cancer. He has been PI on an R01 investigating miRNA as a noninvasive risk stratification tool for prostate cancer, and will soon start new one looking examining the black box of pathology artificial intelligence algorithms through the lens of spatial multi-omics. He serves as Urology co-Leader for the UCSF Helen Diller Family Comprehensive Cancer Center Prostate Program and is also Chief of Urology at the San Francisco VA Medical Center.

Research Funding

  • August 10, 2016 - July 31, 2021 - Improving Prostate Cancer Outcome Prediction Through Noninvasive exRNA Assessment , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA198145
  • August 8, 2012 - May 31, 2017 - Prospective validation of a multi-marker prostate cancer prediction model , Co-Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA160816

Education

Dartmouth College, Hanover, NH, BA, 1991-95, English
Yale University, New Haven, CT, MD, MPH, 1995-00, Medicine, Health Policy

Honors & Awards

  • 1995
    College honors: summa cum laude, Phi Beta Kappa, high honors in major, Presidential Scholar, Rufus Choate Scholar, B. William Hochman Prize in American Literature
  • 1996
    American Cancer Society Research Fellowship
  • 1999
    AMA John Conley Ethics Essay Contest, honorable mention
  • 2003
    UCSF Prostate Cancer Research Symposium, 2nd place, Clinical Research
  • 2004
    UCSF Prostate, Breast, Prostate SPORE Scientific Retreat, honorable mention, Clinical Research
  • 2005
    Northern California Urology Resident Research Symposium, 1st place, Clinical Research
  • 2006
    Northern California Urology Resident Research Symposium, 3rd place, Clinical Research
  • 2007
    AUA Gerald P. Murphy Prostate Scholar
  • 2007
    Northern California Urology Resident Research Symposium, 2nd place, Clinical Research
  • 2007
    Western Section AUA Miley B. Wesson Resident Essay Contest, 3rd place
  • 2008
    Society of Urologic Oncology Poster Session, 3rd place overall
  • 2008
    Western Section AUA Miley B. Wesson Resident Essay Contest, 3rd place
  • 2008
    Western Section AUA Poster Session I, 1st place
  • 2017
    2016 physician award, Marin Prostate Cancer Information and Support Group

Selected Publications

  1. Raizenne BL, Shee K, Cowan JE, Carroll PR, Cooperberg MR Clinical Comparison of Decipher 1.0 and 1.1 for Localized Prostate Cancer: Results in Prostatectomy and Active Surveillance Patients.  View on PubMed
  2. Eklund M, Thompson IM, Cooperberg MR Screening for Prostate Cancer with a Polygenic Risk Score.  View on PubMed
  3. Maughan BL, Dyrskjøt L, Grivas P, Alcaraz A, Antonarakis ES, Bilen MA, Bivalacqua T, Cooperberg MR, Cheng L, Gupta S The Role of Liquid Biopsy in the Management of Patients with Genitourinary Malignancies.  View on PubMed
  4. Culnan JM, Goryachev SD, Bihn JR, Lee G, Chen DCR, Soloviev O, Zwolinski R, Dulberger KN, Do NV, Paller CJ, Cooperberg MR, Fillmore NR Automated Extraction of Imaging and Pathology Data From Diverse Prostate Cancer Electronic Records.  View on PubMed
  5. Shee K, Pace WA, Liu AW, Cowan JE, Subramanyam V, Agapito C, Washington SL, Cooperberg MR, Carroll PR, Shinohara K, Nguyen HG Determining Optimal Patient Selection for High-intensity Focused Ultrasound for Prostate Cancer.  View on PubMed
  6. Handa N, Shore ND, Cooperberg MR, Davicioni E, Zhao X, Elsouda D, Liu Y, Proudfoot JA, Kuperman G, Russell D, Iwata KK, Schaeffer EM, Ross A Transcriptome profiling of prostatic tumours from ENACT trial patients with or without enzalutamide.  View on PubMed
  7. Nie J, Palmer NR, Pasick RJ, Byron M, de la Calle CM, Washington SL, Kivlahan C, Potter MB, Cooperberg MR Smarter Screening and Treatment (S3T): Mitigating Harm via Age- and Prostate-Specific Antigen-Stratified Screening.  View on PubMed
  8. Shee K, Song JJ, Cowan JE, Wang L, Nie J, Chappidi M, Washington SL, Nguyen HG, Cooperberg MR, Shinohara K, Carroll PR The Natural History of Confirmed Grade Group 1 Prostate Cancer Managed with Active Surveillance in the Modern Era.  View on PubMed
  9. Rojo Domingo M, Do DD, Conlin CC, Bagrodia A, Barrett T, Baxter MT, Cooperberg M, Feng F, Hahn ME, Harisinghani M, Hollenberg G, Javier-Desloges J, Kallis K, Kamran S, Kane CJ, Kessler D, Kuperman J, Lee KL, Levine J, Liss MA, Margolis DJA, Matthews I, Murphy PM, Nakrour N, Ohliger M, Ollison C, Osinski T, Pamatmat AJ, Pompa IR, Rakow-Penner R, Roberts JL, Shabaik AS, Song Y, Song D, Tempany CM, Trecarten S, Wehrli N, Weinberg EP, Woolen S, Xu G, Zhong AY, Dale AM, Seibert TM Reply by Authors.  View on PubMed
  10. Daskivich TJ, Stock SR, Cummings S, Masterson JM, Aronson W, Terris M, Klaassen Z, Kane C, Amling C, Cooperberg M, Guerrios Rivera L, Freedland SJ Risks of Progression After Early Androgen Deprivation Therapy for Biochemical Recurrence After Radical Prostatectomy.  View on PubMed
  11. Cooperberg MR, Grummet J, Eggener SE Re: Rajal B. Shah, Gladell P. Paner, Liang Cheng, et al. Genitourinary Pathology Society and International Society of Urological Pathology White Paper on Defining Indolent Prostate Cancer: Call for a Multidisciplinary Approach. Eur Urol. 2025;88:8-10.  View on PubMed
  12. Cooperberg MR Is uptake of AS in low-risk prostate cancer in Ontario linked to guideline publication?  View on PubMed
  13. Li KD, Carlisle MN, Jarosek S, Patel HV, Faris A, Elliott SP, Cooperberg MR, Carroll PR, Breyer BN Evolving Risk of Urinary Adverse Events Across Localized Prostate Cancer Treatments: A Propensity-weighted Analysis of Surveillance, Epidemiology and End Results-Medicare Data.  View on PubMed
  14. Cooperberg MR Prostate Cancer Active Surveillance Without Biopsy? Not Quite Yet, but Watch This Space.  View on PubMed
  15. Rojo Domingo M, Do DD, Conlin CC, Bagrodia A, Barrett T, Baxter MT, Cooperberg M, Feng F, Hahn ME, Harisinghani M, Hollenberg G, Javier-Desloges J, Kallis K, Kamran S, Kane CJ, Kessler D, Kuperman J, Lee KL, Levine J, Liss MA, Margolis DJA, Matthews I, Murphy PM, Nakrour N, Ohliger M, Ollison C, Osinski T, Pamatmat AJ, Pompa IR, Rakow-Penner R, Roberts JL, Shabaik AS, Song Y, Song D, Tempany CM, Trecarten S, Wehrli N, Weinberg EP, Woolen S, Xu G, Zhong AY, Dale AM, Seibert TM Restriction Spectrum Imaging as a Quantitative Biomarker for Prostate Cancer With Reliable Positive Predictive Value.  View on PubMed
  16. Shee K, Cowan JE, Ding CC, Wang L, Pace W, Greenland N, Simko JP, Washington SL, Shinohara K, Nguyen HG, Cooperberg MR, Carroll PR. Gleason Grade Group 3 Represents a Spectrum of Disease: Results from a Large Institutional Cohort. Eur Urol Focus. 2025 May 14.  View on PubMed
  17. Liang M, Zhao Y, Lin DW, Cooperberg M, Zheng Y Estimating optimally tailored active surveillance strategy under interval censoring.  View on PubMed
  18. Cooperberg MR PARP inhibitors for prostate cancer: for whom and when?  View on PubMed
  19. Chesner LN, Polesso F, Graff JN, Hawley JE, Smith AK, Lundberg A, Das R, Shenoy T, Sjöström M, Zhao F, Hu YM, Linder S, Chen WS, Hawkins RM, Shrestha R, Zhu X, Foye A, Li H, Kim LM, Bhalla M, O'loughlin T, Kuzuoglu-Ozturk D, Hua JT, Badura ML, Wilkinson S, Trostel SY, Bergman AM, Ruggero D, Drake CG, Sowalsky AG, Fong L, Cooperberg MR, Zwart W, Guan X, Ashworth A, Xia Z, Quigley DA, Gilbert LA, Feng FY, Moran AE. Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer. Cancer Discov. 2025 Mar 03; 15(3):481-494.  View on PubMed
  20. Van Blarigan EL, McKinley MA, Washington SL, Cooperberg MR, Kenfield SA, Cheng I, Gomez SL. Trends in Prostate Cancer Incidence and Mortality Rates. JAMA Netw Open. 2025 Jan 02; 8(1):e2456825.  View on PubMed

Go to UCSF Profiles, powered by CTSI